ProImmune REVEAL® MHC-Peptide
Competition Binding Assays
How Strong is Your Competitor?
There are situations when you need to evaluate MHC-binding of peptides not just on its own but how a peptide or peptide-mimetic competes with a known control peptide for binding.
As an extension to our regular ProImmune REVEAL® MHC-peptide binding and rate assays we are now also offering MHC-peptide competition binding assays.
These new assays are currently available for the following HLA-DR supertypes:
HLA-DRB1*01:01, *03:01, *04:01, *04:05, *07:01, *09:01, *11:01, *15:01.
Like our other specialist assays our competition assays turn around rapidly in only a few weeks.
ProImmune REVEAL® Competition Assay Principle
Figure 1. Competition assay principle: A labelled control peptide is bound to the MHC-complex, giving a high baseline signal in an immunoassay. As the peptide is competed away with unlabelled competitor peptide the signal reduces at increasing concentration of competitor peptide. The control peptide is usually a well known HLA-Class II restricted immunodominant T cell epitope which is further known to be restricted to the HLA-DR supertype of interest.
The assay can be adapted to accommodate a range of requirements:
Our Immunology Specialist Sales Team will provide a quotation tailored to your specific project requirements.
Key publication for ProImmune REVEAL® Competition Assay:
Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice
Liselotte Jansson, Kathleen Vrolix, Andrea Jahraus, Keith Martin, David Wraith